The new variant of SARS CoV-2, B.1.1.529 Omicron, was designated as a variant of concern (VOC) by the World Health Organization (WHO). The virus's capacity to bind to ACE2 continues to be a key factor in its pathogenicity. Drugs for prophylactic therapy or preventing adverse effects are still under development. Even though Omicron is more transmissible than delta and resistant to most vaccinations and monoclonal antibodies, we still have at least two authorized monoclonal antibody treatments- Sotrovimab and Evusheld.